PATHOGENETIC ROLE OF SURFACTANT PROTEIN B IN THE FORMATION OF PULMONARY PATHOLOGY IN ANIMALS WITH STREPTOZOTOCIN-INDUCED DIABETES

Authors

  • L. M. Zaiats IVANO-FRANKIVSK NATIONAL MEDICAL UNIVERSITY
  • Y. V. Fedorchenko IVANO-FRANKIVSK NATIONAL MEDICAL UNIVERSITY

DOI:

https://doi.org/10.11603/mcch.2410-681X.2022.i4.13568

Keywords:

streptozotocin-induced diabetes, surfactant protein B

Abstract

Introduction. Nowadays, most researchers consider the lungs to be one of the main targets of diabetes mellitus. According to the literature data, pulmonary surfactants, particularly surfactant protein B play the leading role in the pathogenesis of respiratory diseases.

The aim of the study – to establish the pathogenetic role of surfactant protein B (SP-B) in the formation of lung pathology in animals with streptozotocin-induced diabetes.

Research Methods. The experiments were performed on 88 white male Wistar rats weighing 170–210 g. Animals were divided into three groups: 1 – intact (n=10); 2 – control (n=40); 3 – experimental (n=38) with a model of diabetes mellitus, which was reproduced by intraperitoneal injection of streptozotocin by “Sigma” company (USA), diluted in 0.1 M citrate buffer with a pH of 4.5, at a rate of 60 mg/kg body weight. The control group of animals received an intraperitoneal injection with an equivalent dose of 0.1 M citrate buffer solution with a pH of 4.5. SP-B content in blood serum was determined by Rat enzyme-linked immunosorbent assay (ELISA) kit (Elabscience, the USA) 14, 28, 42, and 70 days after streptozotocin injection.

Results and Discussion. Biochemical studies of blood serum showed an increase in SP-B levels in animals with streptozotocin-induced diabetes at all stages of the research. In particular, serum SP-B levels increased by 8.5 % in 14 days, 37.0 % in 28 days, 54.2 % in 42 days and 74.5 % in 70 days compared to the control group of animals.

Conclusions. During the entire study period, streptozotocin-induced diabetes is accompanied by an increase of surfactant protein B levels in the blood serum which plays a key role in the pathogenesis of lung injury in this pathology.

References

Papinska, A.M., Soto, M., Meeks, C.J., & Rodgers, K.E. (2016). Long-term administration of an­giotensin (1-7) prevents heart and lung dysfunction in a mouse model of type 2 diabetes (db/db) by reducing oxidative stress, inflammation and pathological remo­deling. Pharmacol. Res., 107, 372-380. DOI:10.1016/j.phrs.2016.02.026.

Rajasurya, V., Gunasekaran, K., & Surani, S. (2020). Interstitial lung disease and diabetes. World Journal of Diabetes, 11 (8), 351-357. DOI: 10.4239/wjd.v11.i8.351.

Simo, R., & Lecube, A. (2020). Looking for solutions to lung dysfunction in type 2 diabetes. Ann. Transl. Med., 8 (8), 521. DOI: 10.21037/atm.2020.03.225

Kuziemski, K., Slominski, W., & Jassem, E. (2019). Impact of diabetes mellitus on functional exercise capacity and pulmonary functions in patients with diabetes and healthy. BMC Endocrine Disorders, 19, 2. DOI: 10.1186/s12902-018-0328-1.

Zheng H, Wu J, Jin Z, Yan L-J. (2017). Potential biochemical mechanisms of lung injury in diabetes. Aging and Disease, 1 (8), 7-16. DOI: 10.14336/AD.2016.0627

Chen, X.-F., Yan, L.-J., Lecube, A., Tang, X.. (2020). Editorial: Diabetes and obesity effects on lung function. Fronties in Endocrinology, 11 (462), 1-2. DOI: 10.3389/fendo.2020.00462.

Depicolzuane, L., Phelps, D.S., Floros, J. (2022). Surfactant protein – a function: Knowledge gained from SP-A knockout mice. Frontiers in Pediatrics, 9, 799693. DOI: 10.3389/fped.2021.799693.

Martinez-Calle, M., Olmeda, B., Dietl, P., Frick, M., Perez-Gil, J. (2018). Pulmonary surfactant protein SP-B promotes exocytosis of lamellar bodies in alveolar type II cells, FASEB J., 32 (8), 4600-4611. DOI:10.1096/fj.201701462RR.

Hobi, N., Giolai, M., Olmeda, B., Miklavc, Р., Felder, E., Walther, P. (2016). A small key unlocks a heavy door: The essential function of the small hydrophobic proteins SP-B and SP-C to trigger adsorption of pulmonary surfactant lamellar bodies. Biochimica et Biophysica Acta., 1863, 2124-2134. DOI: http://dx.doi.org/10.1016/j.bbamcr.2016.04.028

Lopez-Rodriguez, E., Perez-Gil, J. (2014). Structure-function relationships in pulmonary surfactant membranes: From biophysics to therapy. Biochimica et Biophysica Acta., 1838, 1568-1585. DOI: htlp://dx.doi.org/10.1016/j.bbamem.2014.01.028.

Agostoni, P., Banfi, C., Brioschi, M., Magri, D., Sciomer, S., Berna, G. et al. (2011). Surfactant protein В and RAGE increases in the plasma during cardiopulmonary bypass: a pilot study. Eur. Respir. J., 37, 841-847. DOI: 10.1183/09031936.00045910.

Robichaud, N.A.S., Khatami, M.H., Saika-Voivod, I., Booth, V. (2019). All-atom molecular dynamics simulations of dimeric lung surfactant protein В in lipid multilayers. Int. J. Моl. Sci., 20 (16), 3863. https://doi.org/10.3390/ijms20163863.

Magri, D., Mariotta, S., Banfi, C., Ricotta, A., Onofri, A., Ricci, A. et al. (2013). Opposite behavior of plasma levels surfactant protein type В and receptor for advanced glycation end products in pulmonary sarcoidosis. Respiratory Medicine, 107, 1617-1624. DOI: htlp://dx.doi.org/10.1016/j.rmed.2013.07.019.

Nguyen, A.B., Rohatgi, A., Garcia, C.K., Ayers, C.R., Das, S.R., Lakoski, S.G. et al. (2011). Interactions between smoking, pulmonary surfactant protein B, and atherosclerosis in the general population: The Dallas Heart Study. Arterioscler. Thromb. Vasc. Biol., 31 (9), 2136-2143. DOI:10.1161/ATVBAHA. 111.228692.

Published

2023-02-28

How to Cite

Zaiats, L. M., & Fedorchenko, Y. V. (2023). PATHOGENETIC ROLE OF SURFACTANT PROTEIN B IN THE FORMATION OF PULMONARY PATHOLOGY IN ANIMALS WITH STREPTOZOTOCIN-INDUCED DIABETES. Medical and Clinical Chemistry, (4), 27–31. https://doi.org/10.11603/mcch.2410-681X.2022.i4.13568

Issue

Section

ORIGINAL INVESTIGATIONS